Endocrine Abstracts

Acromegaly is associated with skeletal fragility and high risk of vertebral fractures (VFs), but the determinants of such a risk are still under investigation and it is not clear whether replacement therapies of coexistent hypopituitarism may influence prevalence and incidence of VFs. In this cross sectional study, fourty acromegaly patients (24 M, 16 F; median age, 57 years; range, 25–72), 20 with active disease, were evaluated for the effects of replacement therapy of c...

Klinefelter syndrome (KS) is a frequent form of male hypogonadism that may be associated with a series of comorbidities potentially affecting quality of life and survival. As a matter of fact, KS was shown to negatively impact skeletal health. However, the studies so far published on this topic were mainly focused on evaluation ofbone mineral density (BMD) and bone microstructure, whereas data on fracture risk are still lacking. In this cross-sectional study, we evaluated for ...

Chronic exposure to GH hypersecretion may alter the physiological balance of the spine through inducing degeneration of intervertebral discs and impaired trophism of facet joints. Moreover, GH in excess may also cause profound deterioration in bone microstructure with consequent increase in risk of fragility vertebral fractures (VFs). In this cross-sectional study,we evaluated for the first time in acromegaly the association between spine imbalance and VFs. Thirty-eight patien...

Introduction: Klinefelter syndrome (KS) is known to be associated with an increased risk of venous thromboembolism and arterial thrombosis, but the aetiology behind this prothrombotic status has not been fully elucidated. The aim of this study was to cross-sectionally investigate the coagulative state in subjects with KS compared to age-matched healthy males.Methods: Coagulation factors assessment, clinical characteristics collection and thrombin generat...

TNM 8th edition introduces changes in the staging of patients with differentiated thyroid carcinoma (DTC). This study aims at assessing the ability of TNM 8th edition in predicting structural recurrence of DTC.480 DTC patients were retrospectively evaluated by 7th and 8th editions of TNM staging systems in relationship with risk stratification, response to therapy and recurrence of disease as defined by 2015 American Thyroid Association (ATA) guidelines. As compared to the 7th...

GH deficiency (GHD) and excess of glucocorticoids are associated with increased risk of fragility fractures. Most adult GHD patients have other pituitary deficiencies, but it is unclear whether these deficiencies or their overreplacement therapies may influence the bone disease occurring in GHD. The aim of this study was to evaluate whether the prevalence of vertebral fractures may be influenced by glucocorticoid replacement therapy in hypopituitary males with GHD. We studied ...

The effects of conventional somatostatin analog (SSA) regimens on glucose homeostasis seem to have minor clinical impact in acromegaly. Recently, we performed a trial showing that high dose octreotide LAR significantly reduces IGF1 in acromegalic patients uncontrolled with conventional SSA doses. In this post-hoc analysis, we evaluated the effects of high doses versus high frequency octreotide LAR on glucose homeostasis (HbA1c, FPG, HOMA-R) in patients with acromegaly e...

Objective: In acromegaly, 25–50% of patients remain uncontrolled with conventional somatostatin analogue (SA) therapy. Evidence suggests that response may be improved by increasing the dose or frequency of administration of SAs. This study evaluated the efficacy and safety of octreotide LAR administered at a high dose or high frequency in patients with acromegaly.Methods: This was a 24-week prospective, multicenter, randomized, open-label trial in p...

Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-G...

Objective: To evaluate the association between testosterone (T) values and clinical outcome of COVID-19.Methods: This is a retrospective single-center study performed on 221 male patients (median age 70.5 years, range 26-93) with COVID-19 and hospitalized in our Institution between November 1st 2020 and January 31st 2021. Patients’ height, weight, BMI, medical history and comorbidities were recorded; at admission, patients underwent sampling for com...